Macquarie Group
HTGM

Macquarie Group’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Macquarie Group’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-14
Closed -$7K – 2158
2018
Q4 		$7K Buy
+14
New +$8.68K ﹤0.01% 2023
2018
Q2 		– Sell
-29
Closed -$19K – 2305
2018
Q1 		$19K Buy
+29
New +$21.8K ﹤0.01% 2086

Other funds holding HTGM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Macquarie Group's HTGM Position: Q1 2019 in Review

Macquarie Group sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q1 2019, closing a stake of 14 shares — an estimated $7K sold.

Macquarie Group first reported a position in HTGM in Q1 2018 and held it in 2 quarters. The position peaked at $19K in Q1 2018. 39 funds tracked by Wall St. Rank hold HTGM as of Q1 2019.

  • Macquarie Group reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Macquarie Group sold 14 HTG Molecular Diagnostics, Inc. Common Stock shares in Q1 2019, an estimated $7K.
  • Macquarie Group first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q1 2018 and held it in 2 quarters.
  • Macquarie Group's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $19K in Q1 2018.
  • 39 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q1 2019.

Based on Macquarie Group's 13F filing for Q1 2019, filed 15 May 2019.